Citadel Advisors’s Palvella Therapeutics PVLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.55M | Buy |
20,472
+17,836
| +677% | +$1.86M | ﹤0.01% | 5578 |
|
|
2025
Q4 | $276K | Buy |
+2,636
| New | +$225K | ﹤0.01% | 10335 |
|
|
2025
Q1 | – | Sell |
-10,408
| Closed | -$125K | – | 15882 |
|
|
2024
Q4 | $125K | Sell |
10,408
-1,278
| -11% | -$20.1K | ﹤0.01% | 11131 |
|
|
2024
Q3 | $196K | Buy |
+11,686
| New | +$171K | ﹤0.01% | 10182 |
|
|
2024
Q2 | – | Sell |
-12,090
| Closed | -$177K | – | 15638 |
|
|
2024
Q1 | $177K | Sell |
12,090
-2,784
| -19% | -$38.8K | ﹤0.01% | 10519 |
|
|
2023
Q4 | $217K | Buy |
14,874
+8,179
| +122% | +$150K | ﹤0.01% | 9789 |
|
|
2023
Q3 | $160K | Sell |
6,695
-18,278
| -73% | -$393K | ﹤0.01% | 10255 |
|
|
2023
Q2 | $331K | Sell |
24,973
-26
| -0.1% | -$1.58K | ﹤0.01% | 8832 |
|
|
2023
Q1 | $1.95M | Sell |
24,999
-578
| -2% | -$66.9K | ﹤0.01% | 5428 |
|
|
2022
Q4 | $2.13M | Buy |
25,577
+64
| +0.3% | +$5.14K | ﹤0.01% | 5360 |
|
|
2022
Q3 | $2.35M | Buy |
25,513
+337
| +1% | +$43.4K | ﹤0.01% | 5290 |
|
|
2022
Q2 | $3.77M | Sell |
25,176
-849
| -3% | -$155K | ﹤0.01% | 4332 |
|
|
2022
Q1 | $6.31M | Sell |
26,025
-151
| -0.6% | -$39.7K | ﹤0.01% | 3730 |
|
|
2021
Q4 | $7.92M | Sell |
26,176
-2,697
| -9% | -$864K | ﹤0.01% | 3467 |
|
|
2021
Q3 | $11.9M | Buy |
28,873
+2,822
| +11% | +$983K | ﹤0.01% | 2760 |
|
|
2021
Q2 | $7.98M | Buy |
26,051
+11,574
| +80% | +$2.54M | ﹤0.01% | 3489 |
|
|
2021
Q1 | $2.98M | Buy |
14,477
+392
| +3% | +$85.7K | ﹤0.01% | 5465 |
|
|
2020
Q4 | $2.82M | Sell |
14,085
-311
| -2% | -$64.7K | ﹤0.01% | 4687 |
|
|
2020
Q3 | $2.38M | Sell |
14,396
-113
| -0.8% | -$25.7K | ﹤0.01% | 4405 |
|
|
2020
Q2 | $3.6M | Sell |
14,509
-607
| -4% | -$142K | ﹤0.01% | 3555 |
|
|
2020
Q1 | $2.76M | Buy |
15,116
+344
| +2% | +$86.7K | ﹤0.01% | 3606 |
|
|
2019
Q4 | $4.28M | Buy |
14,772
+13,160
| +816% | +$3.65M | ﹤0.01% | 3270 |
|
|
2019
Q3 | $440K | Sell |
1,612
-383
| -19% | -$148K | ﹤0.01% | 6960 |
|
|
2019
Q2 | $750K | Buy |
1,995
+277
| +16% | +$82.6K | ﹤0.01% | 6173 |
|
|
2019
Q1 | $461K | Sell |
1,718
-380
| -18% | -$90.3K | ﹤0.01% | 6925 |
|
|
2018
Q4 | $446K | Sell |
2,098
-322
| -13% | -$99.9K | ﹤0.01% | 6568 |
|
|
2018
Q3 | $1.08M | Buy |
2,420
+1,499
| +163% | +$651K | ﹤0.01% | 5405 |
|
|
2018
Q2 | $373K | Buy |
921
+239
| +35% | +$114K | ﹤0.01% | 6858 |
|
|
2018
Q1 | $372K | Buy |
682
+554
| +433% | +$343K | ﹤0.01% | 6387 |
|
|
2017
Q4 | $77K | Buy |
+128
| New | +$59.5K | ﹤0.01% | 7507 |
|
Other funds holding PVLA
SCM
FLAM
BI
FLSM
VCM
Citadel Advisors's PVLA Position: Q1 2026 in Review
Citadel Advisors increased its Palvella Therapeutics (PVLA) stake by 677% in Q1 2026, buying an estimated $1.86M and bringing the position to 20,472 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #5578.
Citadel Advisors first reported a position in PVLA in Q4 2017 and has held it in 30 quarters since. The position peaked at $11.9M in Q3 2021. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.
- Citadel Advisors held 20,472 shares of Palvella Therapeutics worth $2.55M as of Q1 2026.
- Citadel Advisors bought 17,836 Palvella Therapeutics shares in Q1 2026, an estimated $1.86M.
- Palvella Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5578 holding.
- Citadel Advisors first reported a position in Palvella Therapeutics in Q4 2017 and has held it in 30 quarters since.
- Citadel Advisors's Palvella Therapeutics position peaked at $11.9M in Q3 2021.
- 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.